Salesforce Q2 Results Met with Caution as Growth Trajectory Remains Uncertain

Salesforce's Q2 results have been met with caution from analysts at Cestrian Capital Research, who maintain a 'hold' recommendation on the stock. The investment firm suggests that Salesforce's growth trajectory is uncertain, hence their decision to hold onto the stock rather than recommending it for sale or purchase. In fact, they note that prices above $165 per share could make the stock less attractive.

The analysts at Cestrian Capital Research also emphasize that this warning applies specifically to US recipients and not to UK investors due to regulatory differences. They reiterate that their analysis is not intended as investment advice but rather a commentary on the company's prospects.

It's worth noting that this recommendation comes with a clear caveat: nothing in this note should be relied upon for making investment decisions. This serves as a reminder of the importance of doing one's own research and seeking professional advice before investing.